| SCN1A — Sodium Voltage-Gated Channel Alpha Subunit 1 | |
|---|---|
| Symbol | SCN1A |
| Full Name | Sodium Voltage-Gated Channel Alpha Subunit 1 |
| Chromosome | 2q24.3 |
| NCBI Gene | 6335 |
| Ensembl | ENSG00000144285 |
| OMIM | 182389 |
| UniProt | P35499 |
| Protein Name | Nav1.1 (Sodium channel voltage-gated alpha subunit 1) |
| Channel Type | Voltage-gated sodium channel (NaV) |
| Ion Selectivity | Na+ > K+ |
| Tissue Expression | Cerebral cortex, Hippocampus, Cerebellum, Brainstem |
| Diseases | Dravet Syndrome, Febrile Seizures, Genetic Epilepsy with Febrile Seizures Plus (GEFS+), Lennox-Gastaut Syndrome, Early Myoclonic Encephalopathy |
Scn1A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SCN1A (Sodium Voltage-Gated Channel Alpha Subunit 1) is a gene located on chromosome 2q24.3 that encodes the Nav1.1 voltage-gated sodium channel. This channel is predominantly expressed in fast-spiking GABAergic inhibitory interneurons, particularly parvalbumin-positive and somatostatin-positive interneurons. SCN1A mutations are the primary genetic cause of Dravet syndrome, one of the most severe genetic epilepsy syndromes. The gene is catalogued as NCBI Gene ID 6335 and OMIM 182389.
Nav1.1 is a large transmembrane protein (~2000 amino acids) organized into four homologous domains (I-IV), each containing six transmembrane segments (S1-S6). The S4 voltage sensor detects membrane potential changes, while the P-loop between S5 and S6 forms the ion selectivity filter 1. Nav1.1 shares structural homology with other neuronal sodium channels (Nav1.2, Nav1.3, Nav1.6) but has distinct functional properties.
Nav1.1 exhibits rapid activation and fast inactivation kinetics typical of neuronal sodium channels. The channel activates at membrane potentials around -40 mV and reaches peak conductance within 1-2 ms. Fast inactivation occurs within milliseconds, mediated by the intracellular III-IV linker acting as a hinged lid 2. Recovery from inactivation occurs during repolarization, allowing channels to participate in subsequent action potentials.
In the brain, Nav1.1 is highly enriched in GABAergic inhibitory interneurons, particularly:
This selective expression pattern explains why SCN1A mutations primarily disrupt inhibitory circuit function 3.
Nav1.1 is essential for the excitability of inhibitory interneurons. Loss-of-function mutations reduce sodium current in these neurons, impairing their ability to fire action potentials and provide inhibitory drive to excitatory pyramidal neurons. The resulting disinhibition leads to hyperexcitability of cortical circuits and seizure generation 4.
The selective vulnerability of inhibitory neurons to SCN1A mutations creates a paradoxical situation: excitatory neurons become overactive due to reduced inhibition. This mechanism differs from gain-of-function sodium channel mutations (e.g., SCN2A), which directly increase excitatory neuron excitability. Understanding this distinction is crucial for developing targeted therapies 5.
Dravet syndrome (also known as Severe Myoclonic Epilepsy of Infancy, SMEI) is a catastrophic early-onset epilepsy syndrome caused by de novo SCN1A mutations in approximately 80% of cases. Key features include:
The R1407X nonsense mutation and N1418H missense mutation are among the most common pathogenic variants 6.
GEFS+ is a milder spectrum disorder caused by inherited SCN1A mutations with incomplete penetrance. Affected family members may have:
Paradoxically, sodium channel blockers (e.g., carbamazepine, phenytoin) can worsen Dravet syndrome in some cases by preferentially affecting remaining functional channels. However, certain agents may be beneficial:
| Drug | Considerations |
|---|---|
| Stiripentol | GABA-A modulator, first-line for Dravet |
| Clobazam | Benzodiazepine, enhances GABA |
| Valproic acid | Broad-spectrum anticonvulsant |
| Cannabidiol | FDA-approved for Dravet |
Novel approaches under investigation:
The study of Scn1A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page last updated: 2026-03-06